Can This Biotech Roar Past $300?
In the following video, Fool contributor Maxx Chatsko reviews the biggest catalysts for Regeneron's recent climb and near-rendezvous with $300 per share. The emerging biotech powerhouse has treated investors well in recent years -- returning more than 1,200% since 2008. While the company no doubt has a promising future, investors may be curious if things are getting too hot too fast. Did investors overreact to prior developments this year? Are shares priced for perfection? Or is $300 per share a benchmark that is actually within reach? The key lies in the pipeline.
While looking at 2012 performance is useful, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Can This Biotech Roar Past $300? originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and emerging technologies. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.